Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers

British Journal of Cancer

Volumn 105, Issue 12, 2011, Pages 1818-1824

  Braicu, E I ^a   Sehouli, J ^a   Richter, R ^a   Pietzner, K ^a   Denkert, C ^a   Fotopoulou, C ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Ovarian carcinogenesis; Primary cytoreduction; Survival; Tumour pattern; Type I and type II tumours

Indexed keywords

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; FOLLOW UP; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; OPERATION DURATION; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL PREDICTION; SURVIVAL RATE; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA; ADOLESCENT; ADULT; AGED; FEMALE; FEMALE GENITAL TRACT TUMOR; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; GENITAL NEOPLASMS, FEMALE; HUMANS; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856007415     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.455     Document Type: Article

References (26)

1. Bamias A, Psaltopoulou T, Sotiropoulou M, Haidopoulos D, Lianos E, Bournakis E, Papadimitriou C, Rodolakis A, Vlahos G, Dimopoulos MA (2010) Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer 116(6): 1462-1468
2. Bell DA (2005) Origins and molecular pathology of ovarian cancer. Mod Pathol 18(Suppl 2): 19-32
3. Blagden S, Gabra H (2008) Future directions in the management of epithelial ovarian cancer. Future Oncol 4: 403-411 (Pubitemid 351984091)
4. Blagden S, Gabra H (2009) Promising molecular targets in ovarian cancer. Curr Opin Oncol 21(5): 412-419
5. Eltabbakha GH, Mountb SL, Beattyb B, Simmons-Arnoldb L, Cooperb K, Morgan A (2004) Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol 95: 377-383 (Pubitemid 39445875)
6. Fotopoulou C, Richter R, Braicu EI, Schmidt SC, Lichtenegger W, Sehouli J (2010) Can complete tumour resection be predicted in advanced primary epithelial ovarian cancer? A systematic evaluation of 360 consecutive patients. Eur J Surg Oncol 36(12): 1202-1210
7. Fotopoulou C, Richter R, Braicu IE, Schmidt SC, Neuhaus P, Lichtenegger W, Sehouli J (2011) Clinical outcome of tertiary surgical cytoreduction in patients with recurrent epithelial ovarian cancer. Ann Surg Oncol 18(1): 49-57
8. Gershenson DM (2010) The heterogeneity of epithelial ovarian cancer: getting it right. Cancer 116(6): 1400-1402
9. Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ (2009) Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol 114(1): 48-52
10. Goff BA, Sainz de la Cuesta R, Muntz HG, Fleischhacker D, Ek M, Rice LW, Nikrui N, Tamimi HK, Cain JM, Greer BE, Fuller Jr AF (1996) Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 60(3): 412-417 (Pubitemid 26077628)
11. Ho CM, Huang YJ, Chen TC, Huang SH, Liu FS, Chang Chien CC, Yu MH, Mao TL, Wang TY, Hsieh CY (2004) Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 94(1): 197-203
12. International Federation of Gynecology and Obstetrics (1987) Changing in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 156: 263-264
13. Kurman RJ, Shih IeM (2008) Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27(2): 151-160 (Pubitemid 351450677)
14. Kurman RJ, Shih IeM (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34(3): 433-443
15. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IeM (2008) Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 198(4): 351-356 (Pubitemid 351451941)
16. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos HP, Efstathiou E, Salamalekis E, Farmakis D, Skarlos D, Briasoulis E, Economopoulos T, Dimopoulos MA (2005) Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 97(2): 436-441 (Pubitemid 40614887)
17. Sehouli J, Könsgen D, Mustea A, Oskay-Ozcelik G, Katsares I, Weidemann H, Lichtenegger W (2003) ['IMO'-intraoperative mapping of ovarian cancer]. Zentralbl Gynakol 125(3-4): 129-135
18. Sehouli J, Richter R, Braicu EI, Bühling KJ, Bahra M, Neuhaus P, Lichtenegger W, Fotopoulou C (2010a) Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 240 consecutive patients. J Surg Oncol 102(6): 656-662
19. Sehouli J, Savvatis K, Braicu EI, Schmidt SC, Lichtenegger W, Fotopoulou C (2010b) Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis. Int J Gynecol Cancer 20(8): 1331-1340
20. Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Werner L, Gülten OO (2009) Intra-abdominal tumour dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol 99(7): 424-427
21. Shih IeM, Kurman RJ (2004) Ovarian tumourigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164(5): 1511-1518 (Pubitemid 38529752)
22. Shih IeM, Kurman RJ (2005) Molecular pathogenesis of ovarian borderline tumours: new insights and old challenges. Clin Cancer Res 11(20): 7273-7279 (Pubitemid 41507684)
23. Singer G, Kurman RJ, Chang H-W, Cho SKR, Shih I-M (2002) Diverse tumourigenic pathways in ovarian serous carcinoma. Am J Pathol 160: 1223-1228 (Pubitemid 34411626)
24. Vang R, Shih IeM, Kurman RJ (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16(5): 267-282
25. Wimberger P, Wehling M, Lehmann N, Kimmig R, Schmalfeldt B, Burges A, Harter P, Pfisterer J, du Bois A (2010) Influence of residual tumour on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol 17(6): 1642-1648
26. Zaino RJ, Brady MF, Lele SM, Michael H, Greer B, Bookman MA (2010) Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer 117(3): 554-562